Literature DB >> 25732653

Pituitary diseases and bone.

Gherardo Mazziotti1, Silvia Chiavistelli1, Andrea Giustina2.   

Abstract

Pituitary hormones have direct and indirect effects on bone remodeling, and skeletal fragility is a frequent complication of pituitary diseases. Fragility fractures may occur in many patients with prolactinomas, acromegaly, Cushing disease, and hypopituitarism. As in other forms of secondary osteoporosis, pituitary diseases generally affect bone quality more than bone quantity, and fractures may occur even in the presence of normal or low-normal bone mineral density, making difficult the prediction of fractures in these settings. Treatment of excess and defective pituitary hormone generally improves skeletal health, although some patients remain at high risk for fractures, necessitating treatment with bone-active drugs.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone mineral density; Cortisol; Fractures; Growth hormone; Osteoporosis; Pituitary diseases; Prolactin; Sex steroids

Mesh:

Year:  2014        PMID: 25732653     DOI: 10.1016/j.ecl.2014.10.014

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  13 in total

1.  Skeletal health in adult growth hormone deficiency.

Authors:  Nicholas A Tritos
Journal:  Endocrine       Date:  2016-01-14       Impact factor: 3.633

Review 2.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

Review 3.  Risk of vertebral fractures in hypoparathyroidism.

Authors:  Anna Maria Formenti; Francesco Tecilazich; Raffaele Giubbini; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

4.  Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency.

Authors:  Gherardo Mazziotti; Mauro Doga; Stefano Frara; Filippo Maffezzoni; Teresa Porcelli; Luigi Cerri; Roberto Maroldi; Andrea Giustina
Journal:  Endocrine       Date:  2015-10-03       Impact factor: 3.633

Review 5.  Acromegalic osteopathy.

Authors:  G Mazziotti; F Maffezzoni; S Frara; A Giustina
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

6.  Diurnal Cortisol Concentrations and Growth Indexes of 12- to 48-Month-Old Children From Mexico City.

Authors:  Jose A Rosa-Parra; Marcela Tamayo-Ortiz; Hector Lamadrid-Figueroa; Alejandra Cantoral-Preciado; Alejandra Montoya; Rosalind J Wright; Andrea A Baccarelli; Allan C Just; Katherine Svensson; Robert O Wright; Martha M Téllez-Rojo
Journal:  J Clin Endocrinol Metab       Date:  2018-09-01       Impact factor: 5.958

7.  Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.

Authors:  Sabrina Chiloiro; Gherardo Mazziotti; Antonella Giampietro; Antonio Bianchi; Stefano Frara; Marilda Mormando; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

Review 8.  Hyperprolactinemia and bone.

Authors:  Luigi di Filippo; Mauro Doga; Eugenia Resmini; Andrea Giustina
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

9.  Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.

Authors:  N C van Varsseveld; C C van Bunderen; A A M Franken; H P F Koppeschaar; A J van der Lely; M L Drent
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

10.  High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma.

Authors:  Stefano Frara; Marco Losa; Mauro Doga; Anna Maria Formenti; Pietro Mortini; Gherardo Mazziotti; Andrea Giustina
Journal:  J Endocr Soc       Date:  2018-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.